Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jun;98(24):e15876.
doi: 10.1097/MD.0000000000015876.

Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: A meta-analysis

Cong Lu  1 , Long Zhou  1 , Jing Ouyang  2 , Huajing Yang  2
Affiliations
Meta-Analysis

Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: A meta-analysis

Cong Lu et al. Medicine (Baltimore). 2019 Jun.

Abstract

Background: Lymphocyte-to-monocyte ratio (LMR) was recently proposed as a prognostic factor of ovarian cancer. However, prognostic value of the LMR in ovarian cancer remains inconclusive. The study aimed to assess prognostic value of the LMR in ovarian cancer.

Methods: Seven common databases were comprehensively searched for relevant studies. The analyses were performed for overall survival (OS), progression-free survival (PFS) and clinical parameters. The hazard ratio (HR) and 95% confidence interval (CI) were used to analyze OS and PFS.

Results: A total of 2343 patients with ovarian cancer were included in this meta-analysis. The results showed that a low LMR predicted shorter OS (HR = 1.81, 95% CI = 1.38-2.37, P < .01) and PFS (HR = 1.65 95% CI = 1.46-1.85, P < .01) when compared to a high LMR in ovarian cancer. Besides, a low LMR was significantly associated with advanced clinical stage (P < .01), earlier lymph node metastasis (P = .01), higher carbohydrate antigen-125 levels (P < .01), larger residual tumor (P < .01) and worse chemosensitivity (P < .01) when compared to a high LMR in ovarian cancer.

Conclusion: Low LMR was associated with unfavorable survival in patients with ovarian cancer. LMR could serve as a prognostic biomarker of ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The flow chart of literature search and selection.
Figure 2
Figure 2
The meta-analysis for association between the LMR and OS (a, forest plot; b, sensitivity analysis; c, funnel plot). LMR = lymphocyte-to-monocyte ratio, OS = overall survival.
Figure 3
Figure 3
The meta-analysis for association between the LMR and PFS (a, forest plot; b, funnel plot). LMR = lymphocyte-to-monocyte ratio, PFS = progression-free survival.
Figure 4
Figure 4
The funnel plots for association between the LMR and clinical parameters (a, age; b, histology; c, histologic grade; d, FIGO stage; e, lymph node metastasis; f, CA-125; g, residual tumor; h, chemosensitivity). CA-125 = carbohydrate antigen-125, FIGO = International Federation of Gynecology and Obstetrics, LMR = lymphocyte-to-monocyte ratio.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30. - PubMed
    1. Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013;22:S23–30. - PubMed
    1. Davidson B, Trope CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Womens Health (Lond) 2014;10:519–33. - PubMed
    1. Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012;23Suppl 10:x118–27. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519–29. - PubMed

Publication types